After method development, we used this in-house method to detect HER2-overexpressed CTCs from participants with GC and cancer-naïve participants (CNPs), and to evaluated the concordance of the results between our in-house method and IHC/ISH methods from tumor biopsy. The gene discussed is ERBB2; the disease is cancer.